The study included a total of 238 consecutive patients, enrolled in the Leipzig Heart Center AF ablation registry, who underwent left atrial radiofrequency catheter ablation for symptomatic, drug-refractory paroxysmal or persistent AF. All patients received a transthoracic and transesophageal echocardiography before ablation procedure to exclude left atrial thrombus, and standardized measurements of LAD, left ventricular ejection fraction, interventricular septal enddiastolic dimension, and left ventricular end-diastolic diameter were
C urrent atrial fibrillation (AF) guidelines 1,2 recommend catheter ablation for patients with symptomatic, antiarrhythmic drug refractory AF or as first-line therapy if no or minimal heart disease is present. Single-procedure ablation achieves freedom from AF in 57% 3 to 89%, 4 depending on patient characteristics, ablation strategies, and follow-up. Prediction of rhythm outcome remains challenging, although a recent meta-analysis identified nonparoxysmal AF, valvular AF, and increased left atrial diameter (LAD) as independent clinical predictors for recurring AF. 5 
Clinical Perspective on p 737
In the past 15 years, increasing interest in the genetic background of AF resulted in the identification of common gene variants that associate with AF. 6, 7 However, there is only limited data correlating genotypes with outcomes of AF therapies [8] [9] [10] and in particular with rhythm outcome after AF ablation. [11] [12] [13] Consequently, this study tested the hypothesis that the angiotensin-converting enzyme gene (ACE) insertion/deletion polymorphism associates with AF recurrence after catheter ablation. Using a candidate gene approach, this polymorphism was selected because the ACE deletion allele, ACE D, is associated with increased ACE serum levels, higher cardiac ACE activity, and increased cardiac fibrosis. [14] [15] [16] The ACE D allele was also demonstrated to associate with electric remodeling in patients with lone AF and those with heart disease 17 and has been linked with failure of anti-AF drug therapy and AF recurrence in Chinese-Han. 8, 18 performed. Antiarrhythmic medication (class I and III antiarrhythmic drugs) was stopped before ablation procedure. The study was approved by the local ethics committee (Medical Faculty, University of Leipzig), and all patients gave their written informed consent.
Catheter Ablation
Left atrial catheter ablation was performed according to a previously described approach. 19 In brief, patients were studied under deep propofol sedation with continuous invasive monitoring of arterial blood pressure and oxygen saturation. Nonfluoroscopic 3-dimensional catheter orientation, computed tomographic image integration, and tagging of the ablation sites were performed using Ensite NavX, Ensite Velocity (St. Jude Medical, St. Paul, MN) or CARTO 3 (Biosense Webster, Diamond Bar, CA). Trans-septal access and catheter navigation were performed with a steerable sheath (Agilis, St Jude Medical, St. Paul, MN). Patients presenting with AF at the beginning of the procedure were electrically cardioverted, and ablation was performed during sinus rhythm (ie, AF termination with ablation was not attempted). In all patients, circumferential left atrial ablation lines were placed around the antrum of the ipsilateral pulmonary veins (irrigated tip catheter, preselected tip temperature of 48°C, and maximum power of 30-50 W). In patients with persistent AF, additional linear lesions were added at the left atrial roof, the basal posterior wall, and the left atrial isthmus. Ablation of complex fractionated electrograms was not performed.
After circumferential line placement, voltage and pace mapping along the ablation line were used to identify and close gaps. The isolation of all pulmonary veins with bidirectional block was verified with a multipolar circular mapping catheter and was defined as the procedural end point.
Follow-Up
After ablation procedure, patients were followed up in the outpatient clinic for 12 months. There was no reinitiation of antiarrhythmic drug class I or III therapy after ablation. Anticoagulation therapy was prescribed for ≥3 months and according to the CHA 2 DS 2 -VASc-Score thereafter. Proton pump inhibitors were prescribed for 4 weeks. Recurrence of AF was detected using serial 7-day Holter ECG recordings after a blanking period of 3 months at 3, 6, and 12 months after catheter ablation. When patients' symptoms referred to AF, supplementary ECGs and Holter recordings were arranged. AF recurrence was defined as a documented episode of AF or any other atrial tachycardia lasting ≥30 s. In case of sustained early recurring AF, patients underwent direct-current cardioversion. Further antiarrhythmic drug therapy was left to the assessment of the treating physician.
Genotyping
DNA extraction was performed using a commercial isolation kit (peqGOLD Blood DNA Mini Kit, PeqLab, Erlangen, Germany) according to manufacturer instructions. ACE insertion/deletion polymorphism was detected using polymerase chain reaction. A set of commercially synthesized primers (TibMolBiol, Berlin, Germany, sense primer 5′ CTGGAGACCACTCCCATCCTTTCT 3′ and antisense primer 5′ GATGTGGCCATCACATTCGTCAGAT 3′) were used for polymerase chain reaction. DNA amplification contained between 35 and 40 cycles. Agarose gel electrophoresis and ethidium bromide staining were used to identify the polymerase chain reaction products with lengths of 190 bp (D allele) and 490 bp (I allele) as illustrated in Figure 1 .
Statistical Analysis
Continuous variables are presented as mean±1SD, and categorical variables are presented as frequencies. Comparison of continuous variables was performed using the unpaired Student t test and of categorical variables using the Pearson χ 2 test. To identify predictors of AF recurrence, a multivariable logistic regression was performed. We adjusted for all variables found in univariate analysis with a P value <0.15 in the multivariable logistic regression analysis, along with variables found to be significantly associated with each genotype. A 2-sided P value <0.05 was considered as statistically significant.
Selection of a recessive genetic model (II and ID versus DD) was based on pathophysiologic considerations and previous studies showing (1) a significant association of the ACE DD genotype and AF recurrence in a population of lone AF subjects of Chinese-Han origin, 18 and (2) the highest cardiac ACE activity in DD genotype, while it was similar in II and ID genotypes. 15 Expected and observed genotype frequencies were compared using χ 2 test to evaluate Hardy-Weinberg equilibrium.
The best LAD cutoff was determined by analyzing the receiveroperator characteristics curve (receiver-operator characteristics are found in the online-only Data Supplement).
Results

Patient Characteristics
Patient characteristics of the total study population and stratified by the ACE genotype are summarized in Table 1 . Genotype frequencies were 23%, 44%, and 33% for the ACE II, ID, and DD genotype, respectively, and did not differ significantly from those expected by Hardy-Weinberg equilibrium calculations. DD carriers were more often men and users of inhibitors of the renin-angiotensin-aldosterone system, whereas other clinical, echocardiographic, and procedural variables were comparable among different ACE genotypes.
Predictors for AF Recurrence
Complete pulmonary vein isolation as a procedural end point was achieved in 98% of cases. AF recurrence was observed in 39% between 3 and 12 months. Patients with AF recurrence are compared with patients without AF recurrence in Table 2 . In univariate analysis, recurring AF was associated with persistent AF, longer history of AF, previous antiarrhythmic drug use, previous use of diuretics, increased LAD, increased left ventricular end-diastolic diameter, additional linear ablation lesions, and the ACE DD genotype. Both, unadjusted and adjusted multivariable analyses identified LAD and ACE DD genotype as predictors for AF recurrence (Table 3 ). AF recurrence rates according to LAD and genotype are depicted in Figure 2 .
Receiver-operator characteristics curve analysis showed LAD ≥45 mm as the best cutoff for AF recurrence prediction. A risk score based on left atrial size (LAD≥45 mm) and ACE genotype (ACE DD) was evaluated and allowed identification of groups at low (0 risk factors), intermediate (1 risk factor), or high (2 risk factors) recurrence risk. Odds of AF recurrence were increased 2.75-fold per risk factor (odds ratio, 2.75; 95% confidence interval, 1.657-4.577; P<0.001). The AF recurrence rate was 21.6% in the low-risk group, 39.7% in the intermediate-risk group, and 70% in the highrisk group (Figure 3 ).
Discussion
Main Findings
To the best of our knowledge, this study is the first to investigate the influence of the ACE insertion/deletion polymorphism on AF recurrence after catheter ablation in whites. Analysis of 238 subjects clearly demonstrated an association between ACE DD polymorphism and AF recurrence 3 to 12 months after ablation. In addition, left atrial enlargement contributed to AF recidivism, which is consistent with previous analyses. 5, 20 
Comparison With Previous Studies
In a recent meta-analysis 5 that included 4357 patients with paroxysmal AF, 1083 with persistent AF, and 1777 patients with Please note that 1 patient was lost to follow-up. AAD indicates antiarrhythmic drug; ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II blocker; BB, β-blocker; CCB, calcium channel blocker; IVSd, interventricular septal end-diastolic dimension; LAD, left atrial diameter; LVED, left ventricular end-diastolic diameter; and LVEF, left ventricular ejection fraction; and Ri, renin inhibitor. , and an LAD of >50 mm (odds ratio, 5.10). 5 Both persistent AF and left atrial enlargement were also associated with AF recurrence, and the latter remained as a significant predictor in multivariable analysis of our population. Interestingly, our left atrial cutoff of 45 mm mirrors closely the findings of a previous study. 20 In contrast, patients with valvular heart disease represented only a minority of our population. Only limited data indicate the possibility of genotype-based AF rhythm control therapies. Recently, 2 single nucleotide polymorphisms on chromosome 4q25 (rs2200733, rs10033464), identified in a genome-wide association study to associate with AF, 21 also predicted AF recurrence after catheter ablation. 11 The current patient population is slightly larger, and the follow-up period was extended to 12 months. In addition, the ACE genotype distribution is rather equal, so that one third of the examined population is affected by the ACE DD risk genotype. We could clearly demonstrate that the presence of ACE DD genotype increases the risk of AF recurrence after radiofrequency catheter ablation. These results are in accordance with previous findings on anti-AF drug treatment, where patients with D allele are reported to have poorer response to antiarrhythmic drug therapy. 8
ACE Insertion/Deletion Polymorphism and Functionality in AF Recurrence
It is assumed that higher ACE and consequently higher angiotensin II levels are responsible for increased structural remodeling. Left atrial structural remodeling can be classified as macroscopic, measured as left atrial dilation, or microscopic attributable to left atrial fibrosis. 22 Consistent with previous findings, the ACE polymorphism did not correlate with left atrial enlargement, and in vivo assessment of left atrial fibrosis is technically challenging and therefore not assessed in our study. However, the ACE polymorphism has been found to correlate with abnormal cardiac conduction as manifest in prolongation of PR interval and P-wave duration, both of which are recognized markers of AF risk. 17 Also, it has been shown that the DD genotype leads to increased ACE serum levels and higher cardiac ACE activity. 14, 15 Furthermore, atrial fibrosis is thought to be increased via an angiotensin IImediated increase in transforming growth factor-β1 mRNA expression. 23 Regions of atrial fibrosis are known to result in conduction heterogeneity and increased AF susceptibility. 24 Thus, multiple lines of evidence suggest the theory that ACE DD compared with the II/ID genotype leads to higher cardiac ACE, angiotensin II, and transforming growth factor-β1 levels, which in turn promotes structural remodeling and abnormal cardiac electrophysiology attributable to fibrosis.
Several previous studies have demonstrated that the reversal of electric remodeling occurs early after restoration of sinus rhythm, 25 whereas structural remodeling including fibrosis takes much longer and is the responsible substrate for recurring AF. 26 The association of the ACE DD genotype with a higher rate of recurring AF found in this study supports this concept. Similarly, a very recent study demonstrated that higher transforming growth factor-β1 levels are associated with AF recurrence after catheter ablation. 20 Although this and our study resemble identical concepts in AF prediction after catheter ablation with comparable results, genotyping offers possible advantages compared with fluctuating and nonstandardized laboratory measurements. Although research into the fundamentals of structural remodeling have not yet been exhausted, the use of biomarkers involved in atrial fibrosis turned out as a new promising approach. 
Study Limitations
This study included a highly selected patient population with a high percentage of lone (58%) and paroxysmal (59%) AF. Furthermore, a standardized ablation approach was applied. Consequently, it is not clear whether these findings are comparable with different ablation approaches, such as ablation of complex fractionated electrograms or energy sources or different patient populations.
As recommended previously and commonly applied, we used serial 7-day Holter ECG monitoring to detect AF. However, even with this strategy, asymptomatic AF may have been missed. Because this would affect the entire cohort, a systematic error seems unlikely. Moreover, the follow-up was limited to 12 months and thus possible very late recurrences could not be analyzed.
ACE genotype distribution was different between men and women patients with AF. Further and larger studies are required to replicate this finding and to explore mechanisms and consequences.
The use of renin-angiotensin-aldosterone system modulators such as ACE inhibitors, angiotensin-receptor blockers, or aldosterone antagonist for secondary AF prophylaxis, in general, and after AF ablation, in particular, is controversial. 27 Whether or not genotype-based renin-angiotensin-aldosterone system modulation offers benefits is unknown and should be explored in the future.
Although this study sought to predict rhythm outcome of AF ablation that is applied to a minority of the AF population, identification of new molecular targets for improved drug therapy and the discovery of biomarkers for risk stratification remains a major goal in the management of the growing number of patients with AF. 28 Most importantly, as with all biomarkers, our findings need to be validated in different AF populations undergoing AF catheter ablation. Nevertheless, it is noteworthy that our study was hypothesis driven and based on a previous biological assumption, and so the need for replication is not as strict.
Conclusions
Left atrial enlargement and the ACE DD polymorphism are predictors for AF recurrence after catheter ablation. The association between the ACE DD polymorphism and AF recidivism further supports the use of genetic data for predicting response to AF therapies and highlights the dominant role of fibrosis in AF development.
